<p>Bharat Biotech, the maker of Covaxin, is expecting the World Health Organization (WHO) regulatory approvals for its Covid-19 vaccine by September.</p>.<p>The Hyderabad-based firm on Tuesday said that it has applied to the WHO-Geneva for the Emergency Use Listing (EUL) of Covaxin and “approvals are expected July-September 2021.”</p>.<p>Serum Institute of India manufactured Covishield, a version of the AstraZeneca/Oxford Covid-19 vaccine, received the WHO listing in February. </p>.<p><strong>Also read: <a href="https://www.deccanherald.com/national/national-politics/who-is-responsible-asks-priyanka-as-congress-steps-up-attack-on-modi-govt-over-covid-handling-989915.html" target="_blank">Who is responsible? asks Priyanka as Congress steps up attack on Modi govt over Covid handling</a></strong></p>.<p>Both Covishiled and Covaxin are part of the ongoing Covid-19 immunization programme in the country. </p>.<p>WHO’s EUL is the green light for a vaccine's roll-out globally. It also allows countries to expedite their own regulatory approval to import and administer Covid-19 vaccines.</p>.<p>The EUL assesses the quality, safety and efficacy of Covid-19 vaccines, as well as risk management plans and programmatic suitability, such as cold chain requirements.</p>.<p><a href="https://www.deccanherald.com/tag/coronavirus" target="_blank"><strong>CORONAVIRUS SPECIAL COVERAGE ONLY ON DH</strong></a></p>.<p>WHO, according to its website, has listed the Pfizer/BioNTech vaccine emergency use in December 2020; two AstraZeneca/Oxford Covid-19 vaccines in February; and Covid-19 vaccine developed by Johnson & Johnson in March. It also approved China's Sinopharm earlier this month.</p>.<p>Bharat Biotech has said that the regulatory approvals for its Covaxin are in process in more than 60 countries like the USA, Brazil, Hungary.</p>.<p>“Emergency use authorisations have been obtained in 13 countries,” the company said in a statement.</p>
<p>Bharat Biotech, the maker of Covaxin, is expecting the World Health Organization (WHO) regulatory approvals for its Covid-19 vaccine by September.</p>.<p>The Hyderabad-based firm on Tuesday said that it has applied to the WHO-Geneva for the Emergency Use Listing (EUL) of Covaxin and “approvals are expected July-September 2021.”</p>.<p>Serum Institute of India manufactured Covishield, a version of the AstraZeneca/Oxford Covid-19 vaccine, received the WHO listing in February. </p>.<p><strong>Also read: <a href="https://www.deccanherald.com/national/national-politics/who-is-responsible-asks-priyanka-as-congress-steps-up-attack-on-modi-govt-over-covid-handling-989915.html" target="_blank">Who is responsible? asks Priyanka as Congress steps up attack on Modi govt over Covid handling</a></strong></p>.<p>Both Covishiled and Covaxin are part of the ongoing Covid-19 immunization programme in the country. </p>.<p>WHO’s EUL is the green light for a vaccine's roll-out globally. It also allows countries to expedite their own regulatory approval to import and administer Covid-19 vaccines.</p>.<p>The EUL assesses the quality, safety and efficacy of Covid-19 vaccines, as well as risk management plans and programmatic suitability, such as cold chain requirements.</p>.<p><a href="https://www.deccanherald.com/tag/coronavirus" target="_blank"><strong>CORONAVIRUS SPECIAL COVERAGE ONLY ON DH</strong></a></p>.<p>WHO, according to its website, has listed the Pfizer/BioNTech vaccine emergency use in December 2020; two AstraZeneca/Oxford Covid-19 vaccines in February; and Covid-19 vaccine developed by Johnson & Johnson in March. It also approved China's Sinopharm earlier this month.</p>.<p>Bharat Biotech has said that the regulatory approvals for its Covaxin are in process in more than 60 countries like the USA, Brazil, Hungary.</p>.<p>“Emergency use authorisations have been obtained in 13 countries,” the company said in a statement.</p>
